<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39447251</PMID><DateRevised><Year>2024</Year><Month>10</Month><Day>24</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1873-2518</ISSN><JournalIssue CitedMedium="Internet"><Volume>42</Volume><Issue>26</Issue><PubDate><Year>2024</Year><Month>Oct</Month><Day>23</Day></PubDate></JournalIssue><Title>Vaccine</Title><ISOAbbreviation>Vaccine</ISOAbbreviation></Journal><ArticleTitle>Risk of major adverse cerebro-cardiovascular events following BNT162b2, CoronaVac, and ChAdOx1 vaccination and SARS-CoV-2 infection: A self-controlled case-series study.</ArticleTitle><Pagination><StartPage>126465</StartPage><MedlinePgn>126465</MedlinePgn></Pagination><ELocationID EIdType="doi" ValidYN="Y">10.1016/j.vaccine.2024.126465</ELocationID><ELocationID EIdType="pii" ValidYN="Y">S0264-410X(24)01147-2</ELocationID><Abstract><AbstractText Label="OBJECTIVE" NlmCategory="OBJECTIVE">To assess the potential risk of major adverse cerebro-cardiovascular events (MACCE) associated with COVID-19 vaccination and SARS-CoV-2 infection.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This self-controlled case series study used nationwide health database from Malaysia. The study included individuals aged ≥18 years who were hospitalised between 24 February 2021 and 30 June 2022. Outcomes were composite of MACCE: stroke, acute ischaemic heart disease, and cardiovascular death. Exposures were COVID-19 vaccination and SARS-CoV-2 infection. The risk period was day 1 to day 21 following exposure. Conditional Poisson regression model was used to estimate the incidence rate ratios (IRRs) and 95 % confidence interval (CI) comparing the outcomes in the risk and control periods.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">The risk of MACCE within 21 days after vaccination per 100,000 doses administered were 12.0 (95% CI 11.9-12.1) (BNT162b2), 9.2 (95% CI 9.1-9.3) (CoronaVac), and 6.8 (95% CI 6.6-7.0) (ChAdOx1). The incidence rate ratios showed no increased risk of MACCE associated with the first, second, or third doses of BNT162b2, CoronaVac, and ChAdOx1 vaccines for individuals without prior cardiovascular disease (CVD). This finding was consistent for individuals with CVD. Vaccine booster dose, whether in a homologous or heterologous schedule, did not show increased risk of MACCE. Analysis by ethnic groups detected a slightly elevated risk of MACCE in Indian after the first dose of ChAdOx1 (IRR 1.64; 95% CI 1.08-2.48) in those without CVD. No significant association were observed in other subgroup analyses. SARS-CoV-2 infection was associated with significantly increased risk of MACCE in individuals without CVD (IRR 3.54; 95% CI 3.32-3.76) and with CVD (IRR 1.98; 95% CI 1.61-2.34).</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Our findings support the favourable safety profile of these COVID-19 vaccines and indicate that the overall benefit-risk ratio of the COVID-19 vaccines remains positive.</AbstractText><CopyrightInformation>Copyright © 2024. Published by Elsevier Ltd.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ab Rahman</LastName><ForeName>Norazida</ForeName><Initials>N</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia. Electronic address: norazida@crc.gov.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>King</LastName><ForeName>Teck Long</ForeName><Initials>TL</Initials><AffiliationInfo><Affiliation>Clinical Research Centre, Sarawak General Hospital, Ministry of Health, Sarawak, Malaysia. Electronic address: kingtl@crc.moh.gov.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Peariasamy</LastName><ForeName>Kalaiarasu M</ForeName><Initials>KM</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia; School of Medicine, Taylor's University, Selangor, Malaysia.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sivasampu</LastName><ForeName>Sheamini</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Institute for Clinical Research, National Institutes of Health, Selangor, Malaysia. Electronic address: sheamini@crc.gov.my.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><CollectiveName>SAFECOVAC study group</CollectiveName></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>10</Month><Day>23</Day></ArticleDate></Article><MedlineJournalInfo><Country>Netherlands</Country><MedlineTA>Vaccine</MedlineTA><NlmUniqueID>8406899</NlmUniqueID><ISSNLinking>0264-410X</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">COVID-19 vaccine</Keyword><Keyword MajorTopicYN="N">Cardiovascular disease</Keyword><Keyword MajorTopicYN="N">SARS-CoV-2</Keyword><Keyword MajorTopicYN="N">Vaccine safety</Keyword></KeywordList><CoiStatement>Declaration of competing interest The authors declare that they have no known competing financial interests or personal relationships that could have appeared to influence the work reported in this paper.</CoiStatement></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>3</Month><Day>11</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>9</Month><Day>23</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>10</Month><Day>15</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>10</Month><Day>25</Day><Hour>0</Hour><Minute>21</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>10</Month><Day>24</Day><Hour>18</Hour><Minute>1</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39447251</ArticleId><ArticleId IdType="doi">10.1016/j.vaccine.2024.126465</ArticleId><ArticleId IdType="pii">S0264-410X(24)01147-2</ArticleId></ArticleIdList></PubmedData></PubmedArticle>